Innovative approaches target PAR2 receptor to alleviate gut pain
Abdominal pain is a hallmark of many digestive disorders, including inflammatory bowel disease and irritable bowel syndrome. In…
What will TrumpRx mean for patients? Who saves — and how much
Could “TrumpRx” be the prescription for lower drug prices? President Donald Trump announced a landmark deal with Pfizer…
From pharmaceuticals to kitchen cabinets, Trump’s tariff program expands
US consumers have been spared largely from the inflationary effects of the Trump administration tariffs so far, but…
Big Pharma’s retreat: Is NHS pricing behind investor pullbacks?
ADVERTISEMENT Relations between Big Pharma and the UK government are under growing strain. Just last week, Eli Lilly…
Lilly’s Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer’s disease
Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with…
Natural Plant Compound Shows Promise for Treating Gum Disease
A natural compound called morin, found in fruits, teas, and nuts, is showing promise as a new tool…
Study Finds Common Meds Leave Lasting Imprints on the Gut, Even Years After You Stop Taking Them
Medications may leave microbial “fingerprints” that last years after use, according to new research from the University of…
Trump administration to link Tylenol to autism, report says
Trump administration officials plan to link the active ingredient in Tylenol to autism Monday, The Washington Post reported,…
FDA cracks down on prescription drug ads but lacks staff
WASHINGTON – In an unprecedented move, federal regulators published about 100 warning letters sent to pharmaceutical companies and health…
Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug
The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy…
Let the rulemaking begin: Why direct-to-consumer drug ads deserve a closer look
Call it death by disclosure. After nearly 30 years in which prescription drug ads have become a fixture…
Small business failure risk in Australia outpaces sector growth
Small business failure risk in Australia is increasing at a faster rate than the pace of overall business…